Lancet. 2014;384:591 8. S4.4-37. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure low- ering on outcome incidence in hypertension: 2. Effects at different baseline and achieved blood pressure levels overview and meta- analyses of randomized trials. J Hypertens. 2014;32:2296 304. S4.4-38. Thompson AM, Hu T, Eshelbrenner CL, et al. Antihypertensive treat- ment and secondary prevention of cardiovascular disease events among persons without hypertension: a meta-analysis. JAMA. 2011;305:913 22. S4.4-39. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure low- ering on outcome incidence in hypertension: 7. Effects of more vs. less intensive blood pressure lowering and different achieved blood pressure levels updated overview and meta-analyses of random- ized trials. J Hypertens. 2016;34:613 22. S4.4-40. Verdecchia P, Angeli F, Gentile G, et al. More versus less intensive blood pressure-lowering strategy: cumulative evidence and trial sequential analysis. Hypertension. 2016;68:642 53. S4.4-41. Bangalore S, Toklu B, Gianos E, et al. Optimal systolic blood pres- sure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med. 2017;130:707 19.e8. S4.4-42. Bundy JD, Li C, Stuchlik P, et al. Systolic blood pressure reduction and risk of cardiovascular disease and mortality: a systematic review and network meta-analysis. JAMA Cardiol. 2017;2:775 81. S4.4-43. Ruggenenti P, Perna A, Loriga G, et al. Blood-pressure control for renoprotection in patients with non-diabetic chronic renal disease (REIN-2): multicentre, randomised controlled trial. Lancet. 2005;365:939 46. S4.4-44. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pres- sure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421 31. S4.4-45. Upadhyay A, Earley A, Haynes SM, et al. Systematic review: blood pressure target in chronic kidney disease and proteinuria as an effect modifier. Ann Intern Med. 2011;154:541 8. S4.4-46. 